-
The company completed round C of $100 million in financing
Time of Update: 2021-03-07
Currently, the company is conducting two Phase I clinical trials initiated by researchers, including the GC012F self-cell candidate developed under the FasTCAR platform for the treatment of recurring or refractic multiple myeloma (r/r MM), and the GC027 isomorphosis product developed under the TruUCAR platform for the treatment of recurring or refractic T-cell acute lymphoblastic leukemia (r/r-ALL).
-
East China Pharmaceuticals acquired a 20% stake in Swiss boric acid enterprises plus the layout of the field of medical beauty
Time of Update: 2021-03-07
In the field of anti-tumor, East China Pharmaceuticals and ImmunoGen signed a $305 million cooperation agreement to introduce the world's exclusive anti-ovarian cancer ADC drug, marking the company's full-scale entry into the field of innovative cancer drugs.
-
Kyusju Tong acquires step-by-step subsidiary to undertake prescription outflow
Time of Update: 2021-03-07
Data show that Kyusju Tong, as the country's largest private pharmaceutical circulation enterprises, mainly to primary medical institutions pharmacies and private hospitals as the object, to provide drug sales and distribution services, so the company has a strong logistics and distribution capacity and terminal resources.
-
These are the keys after national volume procurement
Time of Update: 2021-03-07
of 92% is the first step Recently, the first batch of high-value consumables collection officials, a large number of medical device production enterprises participated in this tender collection, both foreign-funded enterprises well-known brands, but also domestic first-line products.
-
AstraZenecom's $1 billion inhaler emergency?
Time of Update: 2021-03-07
Prior to this, Shijiazhuang four drugs, four Trump Reiter pharmaceutical industry, health yuan seaside pharmaceutical | health yuan pharmaceutical group and other 6 enterprises submitted imitation 4 categories of listing applications in the review and approval (in the drug review center).
-
Genesis announced the completion of a $21 million round B financing
Time of Update: 2021-03-07
Genesis has introduced overseas clinical products to China and partnered with overseas partners in global multi-center clinical trials, while developing best-in-class drugs and has launched innovative drug projects for four targets.
-
Crystal Bio completed a $50 million round A financing
Time of Update: 2021-03-07
The company will use the funds to build a globally innovative research and development pipeline and a core eye drug innovation technology platform to meet the medical needs of patients in China and around the world for eye diseases.
-
Large-scale overcapacity Biodiagnosis may become the next air port
Time of Update: 2021-03-07
1, large-scale overcapacity November 12, 2020 Tiancat Double Eleven global carnival season has come to an end, the analysis data seem to be foreshadowing the direction of China's consumer industry, according to Cypress Blue device observation, "Double Eleven" activities, Tmall mask sales decreased by 76.24 percent compared to the outbreak period; What is the current domestic production capacity of protective materials and where will the market develop?
-
600 billion prescription drugs transferred online to split whose cake
Time of Update: 2021-03-07
On November 14th, a number of Chinese pharmacy chain entrepreneurs, through the China Pharmaceutical Materials Association, provided the media with a "communication material on the proposal to vigorously strengthen the safety supervision of the online sale of prescription drugs".
-
The three major pharmaceutical central enterprises have all entered the bureau of the blood products field pattern or change
Time of Update: 2021-03-07
If this merger is finally completed, the industry believes that with the help of China Resources Pharmaceuticals' state-owned background and predictable government resources, the blood products field may be changing, Boya Bio is expected to become the fifth "thousand tons" plasma company after Hualan Biology, Temple of Heaven Biology, Shanghai Lais, Taibang Bio.
-
The third batch of collections will come to an end, and the west is not the market or will be reconstructed accordingly
Time of Update: 2021-03-07
According to the "National Drug Centralized Procurement Results Table (GY-YD2020-1)" shows that Qilu Pharmaceuticals from the theoretical point of view of the next year in the medical institutions to sell less than 5 million pieces of Xidi Nafei, less than 10% of Baiyunshan Jingo 2019 sales, according to the selected purchase price, its market sales of less than 20 million yuan, but its actual market will be much larger than this, and its impact will be deeper.
-
From next year, these drugs will no longer be reimbursed by Medicare pharmacies
Time of Update: 2021-03-07
, Jiangsu Provincial Medical Security Bureau, Jiangsu Provincial Human Resources and Social Security Department jointly issued "on the publication of basic medical insurance, work injury insurance and
-
Multi-test water online medical reimbursement "Internet plus medical" crack to see a doctor difficult
Time of Update: 2021-03-07
Fu Hongqiao, an associate researcher at Peking University's School of Public Health, said that the new "Internet Plus" health care regulations recently issued by the State Administration of Health Insurance do not discriminate between hospitals and third-party platforms, and clarify the path to the realization of medical insurance payments for third-party Internet medical platforms that rely on physical medical institutions.
-
Health Insurance Bureau: Keep an eye on hospital health insurance loopholes, flight inspection has been targeted
Time of Update: 2021-03-07
At the same time, in 2019, the State Health Insurance Administration sent 69 flight inspection teams to 30 provinces across the country to carry out on-site inspections and interviews with 177 designated medical institutions, and found that the suspected illegal funds amounted to 2.232 billion yuan.
-
China Resources Pharmaceuticals intends to acquire a controlling stake in Boya Biopharmaceutical Group
Time of Update: 2021-03-07
China Resources Pharmaceutical Holdings intends to acquire a controlling stake in the target company, and the terms of the proposed acquisition will not be implemented until further negotiations between China Resources Pharmaceutical Holdings and the seller.
-
Large-scale pharmaceutical industry park project settled in Kunming high-tech zone
Time of Update: 2021-03-07
It can be said that the landing of this large-scale pharmaceutical industry park project has positively responded to the implementation of Yunnan Province biomedicine and large health industry "147" action plan, Kunming High-tech Zone "13th Five-Year Plan" main development of biomedicine and other three major industrial development plans.
-
Drug traceability related policies are initiated in many provinces affecting all pharmacies
Time of Update: 2021-03-07
In addition, on September 21, Hebei Provincial Drug Administration issued a notice, has officially launched the province's Chinese medicine tablets traceability work, 20 production enterprises and 77 franchise enterprises have been included in the retrospective scope for the first time.
-
Huahai Pharmaceuticals' first three quarters of results are soaring sales costs are decreasing
Time of Update: 2021-03-07
a number of pharmaceutical companies, sales costs are falling sharply the performance of well-known pharmaceutical companies October 20, Huahai Pharmaceuticals released the first three quarters
-
Several giant drugstore chains with revenues of more than 20 billion yuan are coming
Time of Update: 2021-03-07
of giant pharmacies with revenues of more than $20 billion are coming In the third quarter of 2020, China National Pharmaceuticals reported a net cash increase of RMB237,928.71 million, or 44,656.29 percent, over the same period last year.
-
Sapp Ace will list its subsidiary Strong Body Pharmaceuticals
Time of Update: 2021-03-07
the evening of November 23rd, Sappes announced that in order to optimize the allocation of resources, improve the profitability of assets and enhance the sustainable development capacity, the compan
